Clinical trials: Biliary Cancers
Hepatectomy, NGS
Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours
The aim of this study is to identify a dysplasia- and CCA-specific NGS panel to increase the diagnostic sensitivity of histological and/or cytological examination of biliary tract stenosis.
- Conditions
- Hepatectomy, NGS, Stenosis of Bile Duct
- Trial name
- NCT06729944
- Testing
- NGS
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Cancer of Biliary Duct
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
- Trial name
- NCT07472933
- Testing
- Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors
- Where
- China
- Volunteers
- 49 people
- Sponsor
- West China Hospital
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Colorectal Cancer
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
- Trial name
- NCT05116891
- Testing
- CAN04 (nadunolimab), mFOLFOX, DTX
- Where
- 6 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- Cantargia AB
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Pancreas Cancer, Surgery-Complications
Relieving the Bile Ducts Prior to Pancreatoduodenectomy
The aim of this study was to assess the risk and complications after preoperative drainage of biliary obstruction in patients who underwent pancreatoduodenectomy.
- Conditions
- Pancreas Cancer, Surgery-Complications, Biliary Fistula
- Trial name
- NCT05434520
- Testing
- Preoperative biliary drainage (ERC og PTC-aided)
- Where
- Denmark
- Volunteers
- 722 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Gastric Cancers
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal…
- Trial name
- NCT01416714
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Chicago
Bile Duct Cancer, Cholangiocarcinoma
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
- Conditions
- Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
- Trial name
- NCT05655949
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Pancreatic Cancer
Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer
The purpose of this study is to evaluate the role of routine Staging Laparoscopy in patients with potentially resectable pancreatobiliary cancer.
- Trial name
- NCT02479984
- Testing
- Staging Laparoscopy, Laparoscopic ultrasound
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- National Cancer Center, Korea
Biliary Tract Tumors
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
- Trial name
- Spring (NCT06892925)
- Testing
- QL1706
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer of the Bile Duct
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
- Trial name
- NCT02115542
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST)
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer
- Trial name
- CURTAIN (NCT07673861)
- Testing
- Marsden360 ctDNA test and GTAB review
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Biliary Tract Cancer
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
- Trial name
- NCT06793709
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Eisai Co., Ltd.
Biliary Tract Cancer
Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
The main objective of the study is to establish if patients with advanced bile duct cancer, who have already received a line of treatment for their disease, will receive any associated benefits from the combination of mFOLFOX6…
- Trial name
- COMBATBIL (NCT05052099)
- Testing
- mFOLFOX6, Atezolizumab and Bevacizumab
- Where
- 2 sites in Germany, Spain
- Volunteers
- 20 people
- Sponsor
- University Hospital, Essen
Unresectable Advanced Solid Tumors, Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
- Trial name
- NCT05527821
- Testing
- Surufatinib, Sintilimab, Short course radiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Biliary Tract Cancer (BTC)
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis.
- Trial name
- NCT04004234
- Testing
- Manganese Chloride, nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Cancer
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
This is a randomized, noncomparative, open-label, exploratory clinical study designed to evaluate the efficacy and safety of sintilimab in combination with NALIRIFOX or gemcitabine plus cisplatin (GP) as first-line treatment for…
- Trial name
- NCT07831993
- Testing
- Sintilimab, Irinotecan Hydrochloride Liposome Injection (II), Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Biliary Tract Cancer (BTC)
Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of Yueju Pill on quality of life and treatment efficacy in patients with advanced biliary tract cancer (BTC)…
- Trial name
- YJ-BTC (NCT07169916)
- Testing
- Yueju Pill + Standard Anti-tumor Therapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.